Skip to content
RegTech Codex
Directory

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Supplied excerpt

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Sources recorded with this draft

The FDA declined to approve one of biotech’s most closely watched cancer drugs | RegTech Codex